Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor-positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03251378
What this trial is testing

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers

Who this might be right for
Advanced Solid TumorsMetastatic Colon CancerMetastatic Breast Cancer+4 more
Hutchison Medipharma Limited 129
Testing effectiveness (Phase 2)Looking for participantsNCT04923542
What this trial is testing

SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

Who this might be right for
Brain MetastasesHR+ Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 31
Not applicableStudy completedNCT06676436
What this trial is testing

Observational Study on the Treatment of Patients With Metastatic Breast Cancer

Who this might be right for
Cancer
AstraZeneca 204
Testing effectiveness (Phase 2)Study completedNCT04699630
What this trial is testing

U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
SCRI Development Innovations, LLC 121
Not applicableStudy completedNCT04460898
What this trial is testing

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

Who this might be right for
Breast Cancer
Pfizer 195
Early research (Phase 1)Ended earlyNCT02964507
What this trial is testing

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Who this might be right for
Neoplasms
GlaxoSmithKline 124
Large-scale testing (Phase 3)Looking for participantsNCT04263298
What this trial is testing

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Herui Yao 210
Not applicableStudy completedNCT04524728
What this trial is testing

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Who this might be right for
BreastNeoplasm MalignantFemale
Istituti Clinici Scientifici Maugeri SpA 191
Testing effectiveness (Phase 2)Study completedNCT03045653
What this trial is testing

Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Sun Yat-sen University 30
Early research (Phase 1)Looking for participantsNCT05304962
What this trial is testing

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Regor Pharmaceuticals Inc. 64
Early research (Phase 1)Active Not RecruitingNCT03959891
What this trial is testing

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Who this might be right for
Breast Cancer
Massachusetts General Hospital 77
Testing effectiveness (Phase 2)UnknownNCT02592746
What this trial is testing

Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

Who this might be right for
Metastatic Breast Cancer
Samsung Medical Center 182
Large-scale testing (Phase 3)Study completedNCT00295620
What this trial is testing

Secondary Adjuvant Long Term Study With Arimidex

Who this might be right for
Breast Cancer
AstraZeneca 3,484
Testing effectiveness (Phase 2)Study completedNCT01068704
What this trial is testing

Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Bristol-Myers Squibb 4
Not applicableStudy completedNCT04671615
What this trial is testing

Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Who this might be right for
Metastatic Breast Cancer
Pfizer 559
Testing effectiveness (Phase 2)WithdrawnNCT00615524
What this trial is testing

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Who this might be right for
Hormone-receptor Positive Breast Cancer
GlaxoSmithKline
Testing effectiveness (Phase 2)Ended earlyNCT00131924
What this trial is testing

High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy

Who this might be right for
Breast Cancer
Northwestern University 1
Testing effectiveness (Phase 2)Study completedNCT05963997
What this trial is testing

Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 49
Not applicableUnknownNCT02109913
What this trial is testing

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Who this might be right for
Hormone Receptor Positive Malignant Neoplasm of BreastMetastatic Breast Cancer
Amsterdam UMC, location VUmc 175
Testing effectiveness (Phase 2)Study completedNCT00602043
What this trial is testing

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast Cancer+2 more
National Cancer Institute (NCI) 20
Next Page